TBIO (telesisbio.com) Business Value to Revenue

Public company logo of Telesis Bio Inc. (TBIO)

Telesis Bio, Inc. (TBIO) generates revenue through the sale of automated systems and consumables for DNA synthesis, which ensures moderate stability of cash flows. This EV/Revenue chart allows for an objective correlation between the business value and its sales, with serving as the current metric level. The integration of BioXp software closes the research cycle, while streamlined international reagent logistics guarantee a seamless supply chain.

TBIO telesisbio.com: Enterprise Value-to-Revenue Ratio in the range 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Telesis Bio, Inc (TBIO)

- price and consensus price forecast:
- business market valuation indicators:
Fundamental valuation:Telesis Bio, Inc. (TBIO)
Manufactured product of Codex DNA

DNA synthesis automation via the BioXp system accelerates pharmaceutical development, making the EV/Sales valuation of Telesis Bio, Inc. (TBIO) a key indicator of the scalability of its technological advantage. This ratio relates the total enterprise value, including debt, to revenue, allowing investors to determine the market premium paid per unit of income and identify the risk of asset overvaluation amid rising operating expenses.

Competitor analysis for Telesis Bio, Inc.

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|Editas Medicine (EDIT) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Silence Therapeutics Inc.|Company Value to Revenue Ratio PRQR (proqr.com)|Enterprise Value-to-Revenue Ratio Codexis Bio (CDXS)|EV/Sales Multiple sangamo.com (SGMO)|Enterprise Value-to-Revenue Ratio nautilus.bio NAUT|Total Company Value-to-Revenue Ratio Metagenomi, Inc (MGX)|Precision BioSciences Inc. - EV/Sales Multiple|GBIO - EV/Sales Multiple|BOLD: EV/Sales Multiple|Company Value to Revenue Ratio XCUR|Enterprise Value-to-Revenue Ratio Imunon|Phio Pharmaceuticals - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Mustang Bio, Inc. (MBIO)|Total Company Value-to-Revenue Ratio TransCode Therapeutics, Inc.|Enterprise Value-to-Revenue Ratio Bionano Genomics BNGO|Business Value to Revenue APDN|BLUE - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume IPA|Omega Therapeutics, Inc. (OMGA) - Enterprise Value-to-Revenue Ratio|Singular Genomics Corp (OMIC) - EV/Sales Multiple|RGLS (Regulus Therapeutics, Inc.) - EV/Sales Multiple|SYRS: Business Value to Revenue|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple